Farms.com Home   Ag Industry News

Cdn. trade disputes stalling ag dealer’s growth

Cdn. trade disputes stalling ag dealer’s growth

Rocky Mountain Equipment withdrew its plan to increase revenues to $1.5 billion

By Diego Flammini
Staff Writer
Farms.com

Canada’s standing in ag trade disputes is the reason behind a company decision to scrap a growth plan, an ag equipment dealer said.

Rocky Mountain Equipment (RME) intended to increase its revenues to at least $1.5 billion by 2023. But the company has put that goal on the backburner because of ongoing diplomatic issues in China, India and Saudi Arabia.

“While some industry fundamentals remain solid, unfortunately, political and macroeconomic issues continue to create significant uncertainty for Canadian farmers and our business,” Garrett Ganden, president and CEO of RME, said in the company’s second quarter results on July 31. “The inability of the Canadian government to make meaningful progress toward improving international trade relations with several key partners only exacerbates this uncertainty.”

RME reported net earnings of only $750,000 in the three-month period ending June 30. That figure is down significantly from 2018 when net earnings for the same time totaled $6.06 million.

The company also reported a 35.7 per cent decrease in sales.

Given ongoing trade uncertainty, farmers are reluctant to invest in newer equipment, Ganden said.

“We need to get some clarity around those macro (economic) conditions … the farmers want to have some understanding of where their end markets are going to be,” he said during a conference call about RME’s earnings, CBC reported.

Sales of some Canadian ag equipment appears to be down across the board.

Sales of 4WD tractors and combines are down by 34.8 and 18.7 per cent respectively, the Association of Equipment Manufacturers said in its June 2019 Ag Tractor and Combine Report.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.